Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction.
McCarroll CS, He W, Foote K, Bradley A, Mcglynn K, Vidler F, Nixon C, Nather K, Fattah C, Riddell A, Bowman P, Elliott EB, Bell M, Hawksby C, MacKenzie SM, Morrison LJ, Terry A, Blyth K, Smith GL, McBride MW, Kubin T, Braun T, Nicklin SA, Cameron ER, Loughrey CM. McCarroll CS, et al. Circulation. 2018 Jan 2;137(1):57-70. doi: 10.1161/CIRCULATIONAHA.117.028911. Epub 2017 Oct 13. Circulation. 2018. PMID: 29030345 Free PMC article.
Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size.
He W, McCarroll CS, Nather K, Ford K, Mangion K, Riddell A, O'Toole D, Zaeri A, Corcoran D, Carrick D, Lee MMY, McEntegart M, Davie A, Good R, Lindsay MM, Eteiba H, Rocchiccioli P, Watkins S, Hood S, Shaukat A, McArthur L, Elliott EB, McClure J, Hawksby C, Martin T, Petrie MC, Oldroyd KG, Smith GL; Oxford Acute Myocardial Infarction (OxAMI) Study; Channon KM, Berry C, Nicklin SA, Loughrey CM. He W, et al. Among authors: mccarroll cs. Cardiovasc Res. 2022 May 6;118(6):1535-1547. doi: 10.1093/cvr/cvab204. Cardiovasc Res. 2022. PMID: 34132807 Free PMC article.
A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.
Kaneko N, Loughrey CM, Smith G, Matsuda R, Hasunuma T, Mark PB, Toda M, Shinozaki M, Otani N, Kayley S, Da Silva Costa A, Martin TP, Dobi S, Saxena P, Shimamoto K, Ishikawa T, Kambayashi R, Riddell A, Elliott EB, McCarroll CS, Sakai T, Mitsuhisa Y, Hirano S, Kitai T, Kusano K, Inoue Y, Nakamura M, Kikuchi M, Toyoda S, Taguchi I, Fujiwara T, Sugiyama A, Kumagai Y, Iwata K. Kaneko N, et al. Among authors: mccarroll cs. Br J Pharmacol. 2024 May 21. doi: 10.1111/bph.16379. Online ahead of print. Br J Pharmacol. 2024. PMID: 38773354